{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:07:33Z","timestamp":1790716053453,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Here we describe a unique case of clozapine-associated hypothermia during initial titration of this medication in an acute inpatient psychiatry setting. Only a handful of cases on this topic have been published. We discuss possible pharmacologic mechanisms supporting or refuting the propensity of clozapine to induce hypothermia, as well as risk factors for clozapine-induced hypothermia, and a comparison to clozapine-induced hyperthermia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 70\u2009year-old African American female with treatment-refractory schizoaffective disorder developed hypothermia with a nadir temperature of 89\u2009\u00b0F (31.7\u2009\u00b0C) after 7\u2009days on clozapine, on a total dose of 50\u2009mg twice daily. Accompanying symptoms included bradycardia, hypotension, QTc prolongation, tachypnea, hypoxemia, and an absence of shivering. The patient was transferred to the ICU, and rewarmed within 10\u2009h with the discontinuation of her clozapine, ziprasidone, and carvedilol. Broad spectrum antibiotics were initiated, but discontinued shortly after, as the patient had no leukocytosis, and blood cultures were negative.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>While hypoglycemia, hypothyroidism, sepsis, and stroke were effectively ruled out, alternative drug-disease (including chronic kidney disease), and drug-drug interactions were considered possible contributing features. Benzodiazepines, valproic acid, ziprasidone, and the numerous antihypertensive agents the patient was taking were considered as either primary or compounding factors for hypothermia. After exclusion or inclusion of these alternative causes, we calculated a score of 4 (possible) for clozapine-induced hypothermia on the Naranjo Scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Clozapine-induced hypothermia may occur more commonly than clinicians believe. Practitioners should be cognizant of this potentially fatal phenomenon, and monitor for temperature dysregulations while on clozapine, especially during initial titration, in those with multiple comorbid factors, and on additional medications that may contribute to hypothermia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-020-02695-w","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T13:20:04Z","timestamp":1591708804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-3785","authenticated-orcid":false,"given":"Bradley G.","family":"Burk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"6","key":"2695_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-007-0294-4","volume":"63","author":"RJ van Marum","year":"2007","unstructured":"van Marum RJ, Wegewijs MA, Loonen AJ, et al. Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol. 2007;63(6):627\u201331.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2695_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2044.1954.tb01927.x","volume":"9","author":"JW Dundee","year":"1954","unstructured":"Dundee JW, Mesham PR, Scott WE. Chlorpromazine and the production of hypothermia. Anaesthesia. 1954;9(4):296\u2013302.","journal-title":"Anaesthesia."},{"issue":"2","key":"2695_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0149-7634(85)90052-1","volume":"9","author":"WG Clark","year":"1985","unstructured":"Clark WG, Lipton JM. Changes in body temperature after administration of amino acids, peptides, dopamine, neuroleptics and related agents: II. Neurosci Biobehav Rev. 1985;9(2):299\u2013371.","journal-title":"Neurosci Biobehav Rev"},{"key":"2695_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fpsyt.2017.00165","volume":"8","author":"C Zonnenberg","year":"2017","unstructured":"Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, et al. Hypothermia due to antipsychotic medication: a systematic review. Front Psychiatry. 2017;8:165.","journal-title":"Front Psychiatry"},{"issue":"7","key":"2695_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1177\/0091270011409233","volume":"52","author":"P Kreuzer","year":"2012","unstructured":"Kreuzer P, Landgrebe M, Wittmann M, et al. Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature. J Clin Pharmacol. 2012;52(7):1090\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2695_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JCP.0000000000000795","volume":"37","author":"TA Scherl","year":"2017","unstructured":"Scherl TA, Langguth B, Kreuzer PM. Hypothermia associated with antipsychotic medication: a clinical surveillance study. J Clin Psychopharmacol. 2017;37(6):751\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2695_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YIC.0000000000000244","volume":"34","author":"AM Szota","year":"2019","unstructured":"Szota AM, Araszkiewicz AS. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. Int Clin Psychopharmacol. 2019;34(1):1\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2695_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1055\/s-2007-986187","volume":"35","author":"S L\u00f6ffler","year":"2008","unstructured":"L\u00f6ffler S, Danos P, Schillen TB, et al. Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy. Psychiatr Prax. 2008;35(2):91\u20133.","journal-title":"Psychiatr Prax"},{"key":"2695_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fpsyt.2019.00543","volume":"10","author":"C Zonnenberg","year":"2019","unstructured":"Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, et al. Antipsychotic-related hypothermia: five new cases. Front Psychiatry. 2019;10:543.","journal-title":"Front Psychiatry"},{"issue":"3","key":"2695_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jamda.2018.12.019","volume":"20","author":"E Schwertner","year":"2019","unstructured":"Schwertner E, Secnik J, Garcia-Ptacek S, et al. Antipsychotic treatment associated with increased mortality risk in patients with dementia. A registry-based observational cohort study. J Am Med Dir Assoc. 2019;20(3):323\u20139.","journal-title":"J Am Med Dir Assoc"},{"key":"2695_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ijcard.2016.06.166","volume":"220","author":"HR Omar","year":"2016","unstructured":"Omar HR, Guglin M. Hypothermia is an independent predictor of short and intermediate term mortality in acute systolic heart failure: insights from the ESCAPE trial. Int J Cardiol. 2016;220:729\u201333.","journal-title":"Int J Cardiol"},{"issue":"26","key":"2695_CR12","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJM199412293312607","volume":"331","author":"DF Danzl","year":"1994","unstructured":"Danzl DF, Pozos RS. Accidental hypothermia. N Engl J Med. 1994;331(26):1756\u201360.","journal-title":"N Engl J Med"},{"issue":"6","key":"2695_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2174\/138920010791636202","volume":"11","author":"JJ Sheehan","year":"2010","unstructured":"Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516\u201325.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"2695_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/JCP.0000000000000877","volume":"38","author":"L Hommers","year":"2018","unstructured":"Hommers L, Scharl M, Hefner G, et al. Comedication of Valproic acid is associated with increased metabolism of clozapine. J Clin Psychopharmacol. 2018;38(3):188\u201392.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2695_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","volume":"28","author":"AP Rajkumar","year":"2013","unstructured":"Rajkumar AP, Poonkuzhali B, Kuruvilla A, et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"2695_CR16","first-page":"2017","volume":"2","author":"OO Ajayi","year":"2017","unstructured":"Ajayi OO, Holroyd S. Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy. BMJ Case Rep. 2017;2:2017.","journal-title":"BMJ Case Rep"},{"key":"2695_CR17","doi-asserted-by":"crossref","unstructured":"Sethi R, Kavuru B. Hypothermia secondary to ziprasidone use in a man with schizophrenia. Prim Care Companion CNS Disord. 2012;14(4).","DOI":"10.4088\/PCC.11l01338"},{"issue":"12","key":"2695_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/qjmed\/95.12.775","volume":"95","author":"ML Mallet","year":"2002","unstructured":"Mallet ML. Pathophysiology of accidental hypothermia. QJM. 2002;95(12):775\u201385.","journal-title":"QJM."},{"key":"2695_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2695_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.siny.2014.10.005","volume":"20","author":"T Wood","year":"2015","unstructured":"Wood T, Thoresen M. Physiological responses to hypothermia. Semin Fetal Neonatal Med. 2015;20(2):87\u201396.","journal-title":"Semin Fetal Neonatal Med"},{"issue":"2","key":"2695_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/JCP.0b013e31819a6a0d","volume":"29","author":"G Papazisis","year":"2009","unstructured":"Papazisis G, Tzellos T, Tahmatzidis D, et al. Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves. J Clin Psychopharmacol. 2009;29(2):183\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"2695_CR22","doi-asserted-by":"crossref","unstructured":"Pelechas E, Tsigaridas N, Kyrama S, et al. Electrocardiographic manifestations in three psychiatric patients with hypothermia - case report. Hell J Cardiol. 2016;8:267\u201370.","DOI":"10.1016\/j.hjc.2015.06.003"},{"issue":"1","key":"2695_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0736-4679(03)00130-6","volume":"25","author":"L Thomas","year":"2003","unstructured":"Thomas L, Pollak PT. Delayed recovery associated with persistent serum concentrations after clozapine overdose. J Emerg Med. 2003;25(1):61\u20136.","journal-title":"J Emerg Med"},{"key":"2695_CR24","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers. Accessed 11\/10\/19."},{"issue":"11","key":"2695_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/0269881110379288","volume":"25","author":"K Windfuhr","year":"2011","unstructured":"Windfuhr K, Turnbull P, While D, et al. The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales. J Psychopharmacol. 2011;25(11):1533\u201342.","journal-title":"J Psychopharmacol"},{"key":"2695_CR26","unstructured":"Novartis Pharmaceuticals. Clozaril (clozapine) package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf. Accessed 12\/2\/19."},{"issue":"10","key":"2695_CR27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1345\/aph.1K126","volume":"41","author":"CM Lowe","year":"2007","unstructured":"Lowe CM, Grube RR, Scates AC. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother. 2007;41(10):1700\u20134.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2695_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/070674370805301211","volume":"53","author":"J Pui-yin Chung","year":"2008","unstructured":"Pui-yin Chung J, Shiu-yin Chong C, Chung KF, et al. The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatr. 2008;53(12):857\u201362.","journal-title":"Can J Psychiatr"},{"issue":"1","key":"2695_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","volume":"1","author":"BD Berman","year":"2011","unstructured":"Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41\u20137.","journal-title":"Neurohospitalist."},{"key":"2695_CR30","doi-asserted-by":"crossref","unstructured":"Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1).","DOI":"10.4088\/PCC.17r02185"},{"issue":"6","key":"2695_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/pcn.12508","volume":"71","author":"YP Hung","year":"2017","unstructured":"Hung YP, Wang CS, Yen CN, et al. Role of cytokine changes in clozapine-induced fever: a cohort prospective study. Psychiatry Clin Neurosci. 2017;71(6):395\u2013402.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"2695_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1345\/aph.1L467","volume":"43","author":"I Kohen","year":"2009","unstructured":"Kohen I, Afzal N, Hussain S, Manu P. Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother. 2009;43(1):143\u20136.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2695_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WNF.0000000000000088","volume":"38","author":"V Bruno","year":"2015","unstructured":"Bruno V, Valiente-G\u00f3mez A, Alcoverro O. Clozapine and fever: a case of continued therapy with clozapine. Clin Neuropharmacol. 2015;38(4):151\u20133.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"2695_CR34","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1124\/jpet.105.092155","volume":"315","author":"ES Burstein","year":"2005","unstructured":"Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist. J Pharmacol Exp Ther. 2005;315(3):1278\u201387.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"2695_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","volume":"177","author":"DM Weiner","year":"2004","unstructured":"Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 2004;177(1\u20132):207\u201316.","journal-title":"Psychopharmacology"},{"issue":"1","key":"2695_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1748-1716.1988.tb08384.x","volume":"133","author":"SO Ogren","year":"1988","unstructured":"Ogren SO, Fuxe K. Apomorphine & pergolide induce hypothermia by stimulation of dopamine D-2 receptors. Acta Physiol Scand. 1988;133(1):91\u20135.","journal-title":"Acta Physiol Scand"},{"issue":"1\u20132","key":"2695_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0014-2999(94)90758-7","volume":"253","author":"P Salmi","year":"1994","unstructured":"Salmi P, Karlsson T, et al. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur J Pharmacol. 1994;253(1\u20132):67\u201373.","journal-title":"Eur J Pharmacol"},{"key":"2695_CR38","first-page":"38","volume":"298","author":"MR Zarrindast","year":"1989","unstructured":"Zarrindast MR. Bromocriptine-induced hypothermia: D-2 receptor involvement. Arch Int Pharmacodyn Ther. 1989;298:38\u201349.","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"9","key":"2695_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0028-3908(99)00064-7","volume":"38","author":"D Boulay","year":"1999","unstructured":"Boulay D, Depoortere R, Perrault G, et al. Dopamine D2 receptor Knock-out mice are insensitive to the Hypolocomotor and hypothermic effects of dopamine D2\/D3 receptor agonists. Neuropharmacology. 1999;38(9):1389\u201396.","journal-title":"Neuropharmacology."},{"issue":"2","key":"2695_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0014-2999(95)00250-O","volume":"280","author":"MJ Millan","year":"1995","unstructured":"Millan MJ, Audinot V, Melon C, et al. Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol. 1995;280(2):225\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2695_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00001756-200001170-00044","volume":"11","author":"S Perachon","year":"2000","unstructured":"Perachon S, Betancur C, Pilon C, et al. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport. 2000;11(1):221\u20135.","journal-title":"Neuroreport."},{"issue":"5\u20136","key":"2695_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00008877-199809000-00008","volume":"9","author":"GB Varty","year":"1998","unstructured":"Varty GB. Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Behav Pharmacol. 1998;9(5\u20136):445\u201355.","journal-title":"Behav Pharmacol"},{"issue":"4","key":"2695_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1476-5381.1987.tb11228.x","volume":"90","author":"G Boschi","year":"1987","unstructured":"Boschi G, Launay N, Rips R. Neuroleptic-induced hypothermia in mice: lack of evidence for a central mechanism. Br J Pharmacol. 1987;90(4):745\u201351.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2695_CR44","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/0028-3908(86)90101-2","volume":"25","author":"GA Gudelsky","year":"1986","unstructured":"Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology. 1986;25(12):1307\u201313.","journal-title":"Neuropharmacology."},{"issue":"2","key":"2695_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0091-3057(95)00122-D","volume":"52","author":"AF Abdel-Fattah","year":"1995","unstructured":"Abdel-Fattah AF, Matsumoto K, El-Hady KA, et al. 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Pharmacol Biochem Behav. 1995;52(2):379\u201384.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"2695_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pbb.2007.10.018","volume":"89","author":"G Neves","year":"2008","unstructured":"Neves G, Kliemann M, Betti AH, et al. Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacol Biochem Behav. 2008;89(1):23\u201330.","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"2695_CR47","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1248\/bpb.18.1580","volume":"18","author":"J Yamada","year":"1995","unstructured":"Yamada J, Sugimoto Y, Horisaka K. Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995;18(11):1580\u20133.","journal-title":"Biol Pharm Bull"},{"key":"2695_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejphar.2018.11.003","volume":"842","author":"TJ Murphy","year":"2019","unstructured":"Murphy TJ, Murnane KS. The serotonin 2C receptor agonist WAY-163909 attenuates ketamine-induced hypothermia in mice. Eur J Pharmacol. 2019;842:255\u201361.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2695_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2010.06.036","volume":"481","author":"PB Hedlund","year":"2010","unstructured":"Hedlund PB, Leopoldo M, Caccia S, et al. LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor. Neurosci Lett. 2010;481(1):12\u20136.","journal-title":"Neurosci Lett"},{"issue":"8","key":"2695_CR50","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.neuropharm.2011.08.022","volume":"61","author":"VS Naumenko","year":"2011","unstructured":"Naumenko VS, Kondaurova EM, Popova NK. On the role of brain 5-HT7 receptor in the mechanism of hypothermia: comparison with hypothermia mediated via 5-HT1A and 5-HT3 receptor. Neuropharmacology. 2011;61(8):1360\u20135.","journal-title":"Neuropharmacology."},{"issue":"4","key":"2695_CR51","doi-asserted-by":"publisher","first-page":"R1097","DOI":"10.1152\/ajpregu.2001.281.4.R1097","volume":"281","author":"CE Black","year":"2001","unstructured":"Black CE, Huang N, Neligan PC, et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am J Physiol Regul Integr Comp Physiol. 2001;281(4):R1097\u2013104.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"2695_CR52","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/bcp.13579","volume":"84","author":"JF Golding","year":"2018","unstructured":"Golding JF, Wesnes KA, Leaker BR. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function. Br J Clin Pharmacol. 2018;84(7):1535\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2695_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuropharm.2009.07.001","volume":"58","author":"D Feifel","year":"2010","unstructured":"Feifel D, Goldenberg J, Melendez G, et al. The acute and subchronic effects of a brain-penetrating, neurotensin1 receptor agonist on feeding, body weight and temperature. Neuropharmacology. 2010;58(1):195\u20138.","journal-title":"Neuropharmacology."},{"issue":"5","key":"2695_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1600-0773.1999.tb01482.x","volume":"84","author":"S Ahlenius","year":"1999","unstructured":"Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol. 1999;84(5):193\u20136.","journal-title":"Pharmacol Toxicol"},{"key":"2695_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbr.2016.02.019","volume":"305","author":"CA Vadnie","year":"2016","unstructured":"Vadnie CA, Ayers-Ringler J, Oliveros A, et al. Antipsychotic-like effects of a neurotensin receptor type 1 agonist. Behav Brain Res. 2016;305:8\u201317.","journal-title":"Behav Brain Res"},{"key":"2695_CR56","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1749-6632.1982.tb31582.x","volume":"400","author":"AJ Prange Jr","year":"1982","unstructured":"Prange AJ Jr, Nemeroff CB. The manifold actions of neurotensin: a first synthesis. Ann N Y Acad Sci. 1982;400:368\u201375.","journal-title":"Ann N Y Acad Sci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02695-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:27:05Z","timestamp":1623194825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02695-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our institutional review board granted consent for publication of encrypted information in this case.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report was obtained from the deceased patient\u2019s family. A copy of the signed written consent to publish is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}